Monday, June 27, 2022

US sees risk of rationing COVID supplies without more funds

The White House is planning dire contingencies that could include rationing supplies of vaccines and treatments this fall if Congress does not approve more money to fight COVID-19.

In public comments and private meetings on Capitol Hill, White House coronavirus coordinator Dr Ashish Jha paints a darker picture of how the US may be forced to abandon the many advances made against the coronavirus in the past two years and here Even the most vulnerable may face shortage of supplies.

Biden administration officials have been warning for weeks that the country has spent nearly all of the money in the US$1.9 trillion rescue plan that was devoted directly to the COVID-19 response.

A small pool of money remains, and the administration is faced with important decisions about how to spend it. This may mean using it to secure the next generation of vaccines to protect the highest-risk populations or prioritizing the supply of highly effective treatments that dramatically reduce the risk of serious illness and death. .

Read Also:  Bitcoin drops below $ 20,000 as cryptocurrency sales accelerate

The decision could be taken in the coming week, according to the administration, as the White House faces deadlines to order vaccines and treatments before other countries overtake the US in accessing supplies.

Jha warns that without more money, vaccines will be harder to come by, tests will once again be scarce, and therapeutics that are helping the country weather the current omicron-driven rise in cases without a corresponding increase in deaths. can be sold overseas. before Americans can reach them.

“I think if this happens we will have to lose a lot of unnecessary lives,” Jha said last week. “But we are looking at all the scenarios and planning for all of them.”

He said the administration was “getting too much into the landscape-planning business to make sure we know what might happen next so that we can plan for it and obviously put it before Congress.”

Read Also:  White House nominates former VOA director for USAGM CEO

Jha, who declined to estimate the potential loss of life, has become the face of the Biden administration’s efforts to persuade Congress to approve an additional $22.5 billion for the COVID-19 response.

“The scenarios we are planning are for things like this if Congress doesn’t give us money and we don’t have enough vaccines,” Jha told Associated Press in an interview on May 12. “We run out of treatment. We don’t have enough tests. What might things look like? Obviously, it’s a very dire situation.”

Already, domestic production of the test is slowing, workers have begun to lay off. In the coming weeks, Jha said, manufacturers would sell the equipment and “get out of this business,” leaving the US once again dependent on foreign suppliers for rapid testing.

A negative COVID-19 test result is displayed on a self-test at home kit provided to Americans free of charge by the US government, May 20, 2022. (Photo by Dia Bekhet)

Drug manufacturers and the Food and Drug Administration, meanwhile, are working on evaluating next-generation vaccines, potentially including those targeted at the major omicron strain. But getting them ready before the expected case increase in the fall means placing orders now, as they take two to three months to produce.

Jha had said this week that the US was yet to initiate talks with drugmakers due to paucity of funds.

“We’ve had some very preliminary talks with the producers,” he said. “But the conversations around it have not started yet, partly because we are waiting for resources.” He added: “The truth is that other countries are in talks with manufacturers and are starting to step up their talks.”

He said the US doesn’t have enough money to buy additional booster vaccines for whoever wants it. Instead, the supply of those vaccines may be limited to only the most vulnerable – not unlike the chaotic early days of the COVID-10 vaccine roll-out.

“Without additional funding from Congress, we would not be able to buy enough vaccines for every American once these new generation of vaccines come out in the fall and winter,” he said.

And while the US has built up a stockpile of the antiviral pill Paxlovid, which has been widely effective in reducing serious illness and death, it is running out of money to buy new doses — or other, even more effective treatments. which are in the final stage of development.

“If we don’t get more resources from Congress, what we will find in the fall and winter is that we will find a time where Americans can see their friends in other countries – in Europe and Canada – with access. These treatments that Americans would not have,” Jha said.

There’s no guarantee of quick action on Capitol Hill, where lawmakers — Republicans in particular — have become newly wary about deficit spending. On Thursday, a $40 billion measure to aid restaurants struggling during the pandemic failed on those grounds. GOP lawmakers have also objected to additional funding for the global pandemic response and called for any new virus response funding to come from the economic relief money unspent in the $1.9 trillion rescue plan.

Due to paucity of money, the administration is preparing to put the blame on the culprits if the difficult consequences of this fall are revealed. Still, it could be dangerous for Biden, who has struggled to keep his promise to voters to get the pandemic under control.

,

This article is republished from – Voa News – Read the – original article.

Nation World News Desk
Nation World News Deskhttps://nationworldnews.com
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news
- Advertisement -